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Key issues in Rett syndrome: emotional,
behavioural and autonomic dysregulation
(EBAD) - a target for clinical trials
Jatinder Singh1 and Paramala Santosh1,2*
Abstract
Complex neurodevelopmental disorders need multi-disciplinary treatment approaches for optimal care. The clinical
effectiveness of treatments is limited in patients with rare genetic syndromes with multisystem morbidity.
Emotional and behavioural dysregulation is common across many neurodevelopmental disorders. It can manifest in
children across multiple diagnostic groups, including those on the autism spectrum and in rare genetic syndromes
such as Rett Syndrome (RTT). There is, however a remarkable scarcity in the literature on the impact of the
autonomic component on emotional and behavioural regulation in these disorders, and on the longer-term
outcomes on disorder burden.
RTT is a debilitating and often life-threatening disorder involving multiple overlapping physiological systems.
Autonomic dysregulation otherwise known as dysautonomia is a cardinal feature of RTT characterised by an
imbalance between the sympathetic and parasympathetic arms of the autonomic nervous system. Unlocking the
autonomic component of emotional and behavioural dysregulation would be central in reducing the impairment
seen in patients with RTT. In this vein, Emotional, Behavioural and Autonomic Dysregulation (EBAD) would be a
useful construct to target for treatment which could mitigate burden and improve the quality of life of patients.
RTT can be considered as a congenital dysautonomia and because EBAD can give rise to impairments occurring in
multiple overlapping physiological systems, understanding these physiological responses arising out of EBAD would
be a critical part to consider when planning treatment strategies and improving clinical outcomes in these patients.
Biometric guided pharmacological and bio-feedback therapy for the behavioural and emotional aspects of the
disorder offers an attracting perspective to manage EBAD in these patients. This can also allow for the stratification
of patients into clinical trials and could ultimately help streamline the patient care pathway for optimal outcomes.
The objectives of this review are to emphasise the key issues relating to the management of EBAD in patients with
RTT, appraise clinical trials done in RTT from the perspective of autonomic physiology and to discuss the potential
of EBAD as a target for clinical trials.
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Background
The Autonomic Nervous System (ANS) can be sepa-
rated into the sympathetic and parasympathetic nervous
system and through multiple overlapping hierarchical
networks; these systems continuously orchestrate and
fine-tune numerous voluntary and involuntary bodily
processes. Any abnormality of the ANS, otherwise
known as dysautonomia or autonomic dysregulation,
leads to a complex physiological picture. Clinically, auto-
nomic dysregulation presents with a constellation of ab-
normalities in different components of the sympathetic
and parasympathetic nervous system. This leads to im-
balances in cardiac, enteric, motor and respiratory sys-
tems resulting in an autonomic crisis. There are several
medical conditions that are due to imbalances in these
systems and some of these include neuroleptic malignant
syndrome, malignant hyperthermia, traumatic brain in-
jury and autonomic dysreflexia [1].
At the genetic level, Riley-Day syndrome otherwise
known as familial dysautonomia is a rare hereditary
autonomic neuropathy caused in the majority of cases
by a mutation in the IKBKAP/ELP1 gene [2]. This gene
encodes the protein IKAP that is a crucial component
for elongator genes, which are thought to be responsible
for the development and maintenance of the ANS [3].
Despite this, the pathophysiology of autonomic dysregu-
lation remains speculative. Studies on the IKBKAP/ELP1
gene pathway have indicated its role in neurological dis-
orders such as those related to intellectual disability [4],
epilepsy [5] and amyotrophic lateral sclerosis [6]. Auto-
nomic failure can also result from other disorders such
as those on the autoimmune and neurological spectrum
including synucleinopathies, autonomic ganglionopathies
and autonomic neuropathies, and have been described
in detail elsewhere [7–10]. From a clinical perspective,
autonomic dysregulation remains a diffuse entity in that
it does not have a standardised and well-defined nomen-
clature that is widely accepted for clinical practice. So
far under its umbrella, more than 30 names have been
coined such as central autonomic dysfunction, paroxys-
mal sympathetic hyperactivity and hypothalamic–mid-
brain dysregulation syndrome [11].
A cardinal feature of autonomic dysregulation is the
disruption of neurotransmitter signalling pathways that
can lead to perturbations in the central and peripheral
release of neurotransmitters. This can give rise to the
manifestations seen clinically and is typically evident in
Rett Syndrome (RTT) whereby brainstem immaturity
[12–14] leads to underdeveloped neurotransmitter path-
ways such as those belonging to the serotonergic neuro-
transmitter system [15, 16]. Others have shown that
increased leptin levels in RTT appear to be associated
with sympathetic over-activity as evidenced by a signifi-
cant correlation between plasma leptin levels and the
LF/HF ratio (an index of sympatho-vagal balance) [17].
Studies in MeCP2 null mice have also implicated
abnormalities in the locus ceruleus to impaired
sympatho-vagal balance [18]. Further research is war-
ranted to confirm these hypotheses.
This review will first introduce autonomic dysfunction
and then describe Emotional, Behavioural and Auto-
nomic Dysregulation (EBAD) in patients with RTT.
Clinical trials done in patients will RTT will then be
placed into context to provide insights that might influ-
ence the development of EBAD as a target for clinical
trials.
Aim
The aim of this review is to appraise clinical trials under-
taken in patients with RTT from the perspective of auto-
nomic dysregulation.
Method
For the purposes of this review freely available biomed-
ical databases PubMed, Cochrane and Scopus were
searched. So that the search could be made more rele-
vant, the Boolean Operator ‘AND’ was used to link the
search terms together. The search words were ‘Rett Syn-
drome AND Clinical Trial.’ To improve the validity of
this search, the following inclusion and exclusion criteria
were implemented into the search strategy:
Inclusion criteria
 Articles in English language in academic journals.
 Peer reviewed articles.
 Articles available electronically.
Exclusion criteria
 Reviews, conference papers, short surveys, notes,
book chapters, editorials, letters and articles in press.
 Articles not in English language.
 Articles not readily accessible electronically.
The search strategy showing the information about
data sources, screening, identification of studies and the
number of studies included is described in Fig. 1.
Autonomic dysfunction in Rett syndrome
Neuronal vulnerability in Rett syndrome
Having an incidence of approximately 1:10,000 live
births [19], RTT is a debilitating neurodevelopmental
disorder predominantly observed in females. In the vast
majority of cases (~ 90%), sporadic functional loss of the
methyl-CpG binding protein 2 (MeCP2) gene causes
RTT, with mutations in CDKL5, FOXG1, CTNNB1 and
WDR45 genes [20–22] contributing to the rarer atypical
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or variant RTT phenotypes. A strong evidence base points
towards the MeCP2 protein being an epigenetic modula-
tor [23–26] with pleiotropic properties binding to more
than 40 structurally diverse proteins [27]. Consistent with
its role as a modulator of chromatin architecture [28]
more recently it was shown that the overarching function
of MeCP2 was to recruit the NCoR/SMRT co-repressor
complex to methylated sites on chromatin [29]. By con-
necting DNA to the NCoR/SMRT complex, it is likely that
the MeCP2 gene has far reaching genome level properties
that have a critical role on the impact of genes regulating
pre- and post-natal neuronal development in either the
upregulation of long (> 100 kb) [30] or short genes [31].
With a wide body of evidence indicating that modulation
of epigenetic mechanisms associated with gene length are
associated with neurodevelopment disorders [32], it un-
derscores the premise that disruption of gene length rep-
resents a major molecular locus of vulnerability for
neurons in RTT. This neuronal vulnerability can manifest
as altered neurogenesis, migration and synaptic integra-
tion, and clinically can present itself as impaired develop-
mental, motor, and social skills.
Autonomic dysfunction
The clinical phenotype of RTT is broad. Being an
X-linked gene, there are marked differences in the
expression of wild-type and mutant alleles [33, 34],
which has an impact on the degree of functional impair-
ment seen in patients [35]. In terms of the degree of
functional impairment, at present autonomic dysfunc-
tion appears not to be governed by a specific mutation
unlike motor or cardio-respiratory phenotypes [35, 36].
Despite this, in patients with RTT the incidence of auto-
nomic dysregulation is very high (~ 75%) [37] and is
regarded to be a key driver of sudden death [38].
The fluidity by which MeCP2 manipulates neuronal
function bestows on it a unique feature that has made
the precise pathophysiology of the autonomic dysregula-
tion seen in patients with RTT difficult to understand.
Nevertheless, autonomic dysregulation has been ex-
plored in patients with RTT [17, 39–46]. One hypothesis
is that unrestrained vagal tone causes a sympatho-vagal
imbalance that is considered unique to patients with
RTT [36]. Sympatho-vagal imbalance might contribute
to about ¼ of the sudden deaths observed in females
with RTT [47, 48], although these numbers are probably
overestimated given the incomplete reporting of the
cause of death in more recent studies [49, 50].
Targeting the clinical phenotype
The clinical phenotype of autonomic dysregulation is highly
variable as individuals can exhibit broad inter-individual dif-
ferences. In RTT, the autonomic dysregulation can overlap
between the sympathetic, parasympathetic and enteric ner-
vous system. Clinically, patients can present with general-
ised anxiety, panic attacks, breathing dysfunction,
temperature dysregulation, peripheral vascular changes, en-
teric changes and cardiac abnormalities, and treatment
often requires a personalised approach. Current strategies
are largely directed towards normalising the symptoms of
autonomic dysregulation in particular modifying the dele-
terious cardio-respiratory phenotype, which not only has a
significant impact on disorder burden [51] but also seems
to be the most viable clinical outcome measure for transla-
tion [52]. Targeting the serotonergic neurotransmitter sys-
tem therefore appears to be a viable symptomatic strategy
[53, 54], and presently studies are underway exploring the
role of a 5-HT1A receptor agonist for the reduction of re-
spiratory impairments in females with RTT [55]. More re-
cently, autonomic dysregulation due to altered levels of
Substance P expression in the brainstem of MeCP2 null
mice was also found to be an associative factor for the re-
spiratory deficits seen in these mice [56]; however, further
work would be warranted in human studies before infer-
ences can be made.
Emotional and Behavioural dysregulation
The interplay between emotion and behaviour
The ANS is the mainstay for the synergistic interplay
governing human emotion and behaviour. In particular,
Fig. 1 Screening process and search results. Notes: * Yuge et al. 2017
(reference: 129); Pini et al. 2016 (reference: 125); Pini et al. 2012
(reference: 119); Signorini et al. 2011 (reference: 115); Haas et al.1986
(reference: 101). ** Based on inclusion/exclusion criteria. Studies done
in animal models, review articles and irrelevant articles were excluded
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the parasympathetic feedback of cardiac tissue via the
vagus nerve provides a means for cardiac-respiratory
output to be regulated to meet ever-changing emotional
and behavioural demands [57]. Disorders in this feed-
back pathway and allied interconnecting networks be-
longing to the anterior cingulate cortex [58] and other
brain regions such as the amygdala [59] are thought to
be key drivers for emotional and behavioural dysregula-
tion seen in a wide range of developmental disorders.
From a developmental perspective, emotional dysregula-
tion in childhood is associated with varied psychiatric
and psychosocial deficits in adolescents [60]. Moreover,
a 14-year prospective follow-up study in 2076 children
showed that emotional dysregulation in childhood con-
fers an increased risk of emotional dysregulation in early
adulthood [61]. It is likely that developmental history in-
fluences the malleability of brain networks and therefore
epigenetic factors associated with childhood adversity or
maltreatment can have a marked impact on the develop-
mental trajectory of behavioural and emotional brain
conduits propagated into adulthood. Indeed, evidence
points towards altered brain networks such as changes
in the threshold of limbic reactivity in response to early
childhood adversity [62] and disrupted fronto-limbic cir-
cuits as the most altered brain regions in those who have
experienced childhood maltreatment [63]. These circuit
changes are also consistent with the premise that these
children are at higher risk of reactive aggression and
autonomic hypo-responsivity [64, 65]. Developmental
traumatology is also believed to alter stress hormone re-
sponses that in turn can modify neuronal morphology in
brain regions resulting in functional perturbations such
as decreased right and left hemisphere integration [66].
In RTT, neuronal vulnerability and the increased elec-
trical irritability of neural circuits produce marked
changes in emotion and behaviour, and the salient points
will be discussed below.
Emotional and Behavioural dysregulation in RTT
Emotional and behavioural dysregulation is frequently
encountered in patients with RTT [51, 67, 68]. In RTT,
the emotional state of the individual can be further exac-
erbated by the physical difficulties observed, for ex-
ample, epileptic seizures can lead to a heightened
emotional state and often leads to anxiety [69] but can
also include screaming, labile mood and uncontrollable
crying [67, 70]. Regarding lifespan, emotion and behav-
iour are thought to change during the time course of
RTT [71, 72]. Behavioural dysregulation can present
with increased stereotypies, repetitive rocking, scratch-
ing, self-injurious or self-stimulatory behaviour, and agi-
tation. Some studies have indicated that emotional and
behavioural impairments such as sleep problems and
screaming in the early stages of RTT may be due to the
occurrence of intellectual disability rather than by RTT
itself [73, 74] and may reduce over time [37, 75]. In
RTT, evidence has shown that individuals with milder
mutations are more likely to exhibit mood disturbances
such as anxiety/inappropriate fear in comparison to indi-
viduals with more severe mutations who were less likely
to report such difficulties [76].
While the precise cause of the emotional and behav-
ioural dysregulation in RTT remains to be established,
developmental deletion of MeCP2 gene in somatosen-
sory neurons in animal models can recapitulate the core
behaviour defects observed in RTT such as anxiety [77].
Recently it was also shown that MeCP2 could restrain
corticotrophin releasing hormone gene expression [78],
which has a key role in maintaining the homeostasis of
the hypothalamic-pituitary-adrenal axis (HPA). Dysregu-
lation of the HPA has been implicated in a variety of
childhood anxiety disorders [79].
Emotional and behaviour dysregulation can have a sig-
nificant impact on the quality of life in patients with
RTT. Despite this, the association of autonomic dysregu-
lation on emotional and behavioural dysregulation in
RTT has not been well developed. The triumvirate con-
sisting of (I) emotion, (II) behaviour and (III) autonomic
function needs to be considered holistically in RTT and
will be discussed in the next section.
Emotional, Behavioural and Autonomic
dysregulation in RTT
Given the nature of the disorder, the emotional and be-
havioural dysregulation seen in patients with RTT has
been difficult to capture. Most of the information relat-
ing to the emotional and behavioural state has been
based on proxy measures such as the motor–behavioural
assessment (MBA) [80], the Rett Syndrome Behavioral
Questionnaire (RSBQ) [81], Anxiety Depression and
Mood Scale (ADAMS) [82], the Vineland Adaptive Be-
haviours Scale [83], the Rett Clinical Severity Score
(RCSS) [84] and the Gross Motor Scale [85]. Quality of
life measures such as the Child Health
Questionnaire-P50 have also been used [86]. Others
have attempted to use direct observation to recognize
the emotional state in patients with RTT [87, 88]; how-
ever, the outcome of the emotional and behavioural state
by observers is poorly defined with no consensus on
agreement by observers and underscores the need for an
individualised approach.
Autonomic function together with emotional and be-
havioural regulation is of interest when capturing clinic-
ally meaningful change longitudinally in patients with
RTT. The symptoms of EBAD and how they present
clinically is shown in Fig. 2. To manage this symptom-
atology, biometric guided therapy can be used to map
the trajectory of EBAD in patients with RTT, and in
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those with a significant functional disability. Heart rate
variability (HRV) is an indirect measure of autonomic
arousal [89, 90] and can be measured using wearable
sensor technology. Wearable sensor technology has been
used as a biometric proxy measure to monitor treatment
outcomes of EBAD in RTT [40, 91] and in those with
other complex neurodevelopmental disorders [92]. In
these cases, sensor-based biometrics can assist in the in-
dividualisation of patient care allowing the management
of patients with EBAD. This strategy is currently being
used in the Centre for Interventional Paediatric Psycho-
pharmacology and Rare Diseases (CIPPRD) [93]. Further
studies are warranted in other routine clinical settings.
Given that EBAD is seen in treatment non-responders
with a significant functional disability frequently encoun-
tered in rare diseases and in those with complex neuro-
psychiatric problems, there is an urgency to provide
effective treatment pathways for these patients. Despite
this, there is a formal lack of guidelines on the manage-
ment of EBAD in patients with RTT and highlights the
need for improvements in knowledge within this area in
particular regarding clinical trials. While RTT specific
anchors [94] and Bayesian approaches [95] have im-
proved outcome measures and the design of rare disease
clinical trials, the ultimate goal is to harmonise interven-
tions that can be used to monitor EBAD in RTT patients
across clinical trials. Autonomic data can help in this re-
gard and might be able to foster the development of bet-
ter outcome measures for clinical trials as was shown
recently in patients with breathing abnormalities [96].
Similarly, in a cohort of RTT patients, biometric data
(electrodermal activity and HRV) has been used to de-
tect an autonomic response to pain [97]. In the next sec-
tion, the potential utility of EBAD as a target in clinical
intervention trials will be discussed.
EBAD as a target for clinical trials in RTT
Given the clinical heterogeneity observed in patients with
RTT, there is unlikely to be a ‘one-size-fits-all’ treatment
approach. Disentangling the heterogeneity of RTT across
individuals has been a real treatment challenge in terms of
providing effective clinical interventions. Traditionally,
Fig. 2 Emotional, Behavioural and Autonomic Dysregulation (EBAD) and its clinical presentation in Rett Syndrome. Abbreviations: EBAD
(Emotional, Behavioural and Autonomic Dysregulation). Notes: a Stress can cause functional changes in epigenetics and it is highly probable that
the epigenetic mechanisms controlled by MeCP2 form a crucial component of the stress response. b Physical problems include seizures, pain and
discomfort, and infections
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such an approach often requires the use of ‘big data’ to
identify patterns of interaction seen across individuals,
and although big data analytics are gaining traction in
psychiatry [98], such approaches are not readily feasible in
RTT given the limited patient population and the difficul-
ties in assessing patients during the life-span of the dis-
order. This has been exemplified in individuals with
Fragile X syndrome (FXS). As a single gene disorder, FXS
was thought to have had amenable drug targets, however,
despite promising studies using animal models, so far, the
translational potential of drug treatment for FXS has failed
to live up to expectation even using well-powered
double-blind placebo-controlled trials [99]. Failure of drug
translatability has prompted the re-assessment of outcome
measures in FXS [100] and underscores the need for more
objective measures for clinical trials in RTT patients that
would be able to capture clinically meaningful change
longitudinally.
Clinical trials in Rett syndrome
From the search strategy (Fig. 1), 34 articles (references:
[101–134]) were identified and appraised. These studies
are summarised in Table 1. Details relating to the differ-
ent domains of EBAD i.e., the emotional, behavioural
and autonomic components have been emphasised in
Table 1. Although none of the studies specifically used
EBAD as a target for clinical trial intervention, a few did
show promise in improving the indices of EBAD
reflected in improvements in emotional, behavioural
and/or autonomic dysregulation.
Autonomic dysfunction reflected by impaired cardiac
output improved following treatment with omega-3
polyunsaturated fatty acids (ω-3 PUFAs). In this study,
subclinical myocardial dysfunction was shown to be par-
tially rescued in patients with RTT by high dose ω-3
PUFAs supplementation for 1 year [122].
Other studies paint a complex picture. Insulin-like
Growth Factor 1 (IGF-1) in its tripeptide form had no
effect on cardiac vagal tone in a study of 6 RTT patients
[119]; however, a later study using full length IGF-1 (also
known as mecasermin) in 12 RTT patients showed im-
provements in breathing and peripheral autonomic func-
tion but no change in communication or motor
functions [124]. An open-label study evaluating the ef-
fects of mecasermin in 10 patients also showed improve-
ments in ISS scores [125]. The International Scoring
System (ISS) is used to assess RTT severity using five
separate subscales one of which considers the
brainstem-autonomic component (subscale v). Despite
some studies showing positive findings, a recent
double-blind crossover trial assessing efficacy of meca-
sermin in 29 patients noted no significant improvements
between treatment groups in the outcome measures
tested [132]. Moreover, in that study a secondary
analysis of subjects not in the placebo arm showed a
worsening of symptoms.
Improvements in gait velocity and breath holding
[127] were observed in patients administered glatiramer
acetate (GA). On the contrary, a similarly designed study
using GA was prematurely terminated due to serious ad-
verse events (SAE) in four patients [128]. The onset of
these SAEs followed administration of GA and the sub-
sequent immediate post-injection reaction was deemed
to be related to primary autonomic dysfunction [128].
Ghrelin has an important role in maintaining the bal-
ance of the parasympathetic and sympathetic nervous
system [135]. In a recent pilot study, two patients with
RTT showed improvements in dystonia, tremor and
vasomotor reflexes following treatment with ghrelin
[129]. It is possible that these improvements in clinical
symptoms may be due to the ghrelin dampening down
the hypertonic state of the sympathetic arm of the ner-
vous system; however, further work would be needed in
a larger sample size and randomised controls to confirm
this finding.
Using a variety of outcome measures, improvements
were noted in the core clinical features following dextro-
methorphan [130] and high dose trofinetide (IGF-1 tri-
peptide analogue) [131] treatment in RTT patients.
Interestingly, in these studies not all parameters that
were evaluated demonstrated improvements. No
changes in either global severity [130] or the apnoea
index [131] were noted in comparison to placebo. This
was shown in a study of desipramine in 26 patients with
RTT whereby no significant differences were found be-
tween treatment groups for apnoea-hypopnea index and
severity [134].
The apparent contradictory findings in some of the
studies previously described raises the question to what
would be considered an optimal design for clinical trials
done in RTT patients where the patient population is
small. Clinical heterogeneity seen in RTT patients could
play a significant role and others have used alternative
clinical trial designs such as the modified stepped wedge
approach to manage the variability in the patient popula-
tion [133]. In some cases, the design of the trials could
be masking the improvements in some core features of
RTT symptomatology from being revealed. Another sig-
nificant problem with trials in rare diseases is the math-
ematical problem of increased variability arising from
multiple evaluators (researchers and clinicians) because
only a few subjects are available from each site partici-
pating in the trial. One strategy to deal with this could
be that a central research site takes the responsibility for
evaluating all the outcomes in a blinded manner, using
digital health strategies or building in limited visits to
the main site for critical time points when outcomes
evaluation is essential. Reduction in evaluator variability
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will improve the likelihood of identifying true differences
between placebo and the experimental drug.
Exaggerated placebo responses can also mask the ac-
tual effect especially in the design of double-blind rando-
mised trials. A large placebo-like response was observed
in children with autism spectrum disorders, whereby
caregivers reported a significant reduction in problem
behaviours in the absence of treatment [136]. Moreover,
one study done in RTT patients has shown a placebo ef-
fect of more than 60% [118]. Whilst wishing not to
speculate on how to reduce the magnitude of the pla-
cebo effect, newer trial designs such as the two-by-two
blind trial design [137] or a result dependent randomisa-
tion algorithm [138] might be adopted to mitigate such
issues.
Nevertheless, these studies have paved the way for piv-
otal trials to be performed and have opened up other
important avenues for consideration such as the use of
stratification biomarkers for patients entering into clin-
ical trials. Some progress has been made in the area, for
example, the use of the frontal band asymmetry index
[124] and visual evoked potentials [139] to assess anx-
iety/depression and brain function respectively. Biomet-
ric guided therapy that monitors the autonomic
component of EBAD in RTT patients can also be used
to guide the stratification of patients entering clinical tri-
als and will be discussed in the next section.
Longitudinal monitoring of EBAD across the lifespan in
patients with RTT
We have shown previously that biometric guided ther-
apy can be used as a multimodal biomarker together
with behavioural and emotional indices to manage
EBAD in patients with RTT and other neurodevelop-
mental disorders [91, 92]. By objectively measuring the
autonomic dysregulation, coupled with both observa-
tional and carer reported measures of behavioural and
emotional dysregulation, EBAD could be considered as a
tangible target for clinical trials. It would be useful in
guiding researchers in improving inclusion criteria and
hence the stratification of patients entering clinical trials.
The inclusion of autonomic parameters has already led
to an improved classification of patients with RTT
allowing for a better prognosis [140]. Whilst this area of
research in RTT is emerging, it is hoped that the
development of new measures using the web-based Health-
TrackerTM health monitoring and analytics system [141]
coupled with improved classification techniques [140] will
boost the predictive power of stratification and allow
researchers to capture clinically meaningful change of
RTT symptomatology across the lifespan. Since RTT
is not a homogeneous disorder but rather charac-
terised by a nebulous developmental heterogeneity,
capturing change across the lifespan would be crucial
when designing stratification strategies for trials. To
improve the clinical utility of such studies at least
three time-points would be required so that EBAD
could be tracked and have prognostic value. The longitu-
dinal trajectory of EBAD has never been evaluated and in
this view, one could have a model whereby EBAD could
be tracked from childhood to adolescence where the
neuro-anatomical and neuro-physiological profiles of RTT
would be different. This may seem as an ambitious under-
taking; however, given the multifaceted nature of RTT,
new tangible outcome measures would be of benefit in
terms of how we evaluate the efficacy of drugs in future
clinical trials in RTT patients.
Conclusions
The take home message from this review is that clinical
trials undertaken in patients with RTT have met with
limited success. None of the studies so far have specific-
ally assessed EBAD and those that have explored auto-
nomic parameters showed a mixed profile on the
efficacy of interventions. Some recent clinical trials have
shown promise in ameliorating the core features in RTT
with improvements in autonomic parameters. However,
given the loss of MeCP2 capacity in fine-tuning neuronal
brain development during early life and therefore trig-
gering changes in the epigenetic states of genes poten-
tially lasting across the life-span [142], it is very likely
that single drug strategies may not be sufficient. Given
the state of dysregulation of multiple overlapping
physiological systems in EBAD, it is probable that there
is a need for a symptom-based approach where different
medications will be needed to manage different symp-
toms that impair subjects with RTT, thus requiring a
truly personalized approach to treatment.
Final remarks and the way forward
RTT is a complex disorder and given its mutational pro-
file; treatment has been a real clinical challenge, how-
ever, this in an exciting time for the RTT field. A
concerted effort is ongoing to optimise clinical trial de-
sign and yet due to the variability in the velocity of clin-
ical presentation, it is vital to identify unifying features
in RTT so that they can be measured across clinical tri-
als. While no outcome measure will be perfect, it would
be of benefit to create better instruments for interven-
tion studies in RTT. The development of the compre-
hensive web based HealthTracker™ Rett Evaluation of
Symptoms and Treatments (REST) questionnaire [141]
along with objective measures such as biometric data is
an important step forward in this area. These measures
can be used to manage EBAD and can help to define
subgroups of patients which will guide researchers to
identify at baseline which group of patients might re-
spond better to a particular treatment in the clinic or a
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drug in a clinical trial. Machine learning might also be a
useful foil to consider. Recently, such an approach was
used to predict motor progression in patients with Par-
kinson’s disease thereby offering up new ways to increase
the cost-effectiveness and efficiency of clinical trial de-
sign [143]. This approach is likely to have clinical value
in RTT as recently machine learning was shown to be
able to overcome inter-subject and inter-trial variability
when classifying respiratory disturbances in patients
with RTT [144]. In a rare disease population, it may also
be appropriate to consider personalised strategies to
measure the effectiveness of medication by using
web-based systems such as the HealthTrackerTM [93].
In summary, a multi-modal holistic approach is war-
ranted to render meaningful clinical improvement in pa-
tients with RTT. The implementation of new outcome
measures such as those focusing on EBAD will provide
researchers with the opportunity to target a number of
systems and aid in the development of better clinical
trial designs.
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